RESUMEN
Kidney renal clear cell carcinoma (KIRC) is the most general subtype of renal cell carcinoma, which composes about 1/20 of adult malignancies. The anomaly of long noncoding RNAs (lncRNAs) expression is proved to mediate cancer progression of various types. The function and mediation mechanism of MSC-AS1 has rarely been detected in KIRC before. This study started with the mediation of MSC-AS1 on cell function. In this study, MSC-AS1 was dramatically upregulated in KIRC and correlated with dismal prognosis of KIRC patients. Knockdown of MSC-AS1 would suppress the proliferative and migratory properties of KIRC cells. MSC-AS1 was found to directly downregulate miR-3924 expression while miR-3924 directly downregulated WNT5A expression. Meanwhile, MSC-AS1 could promote the expression of WNT5A, indicating the existence of MSC-AS1/miR-3924/WNT5A. Further assays indicated that MSC-AS1 could enhance Wnt/ß-catenin pathway. By means of rescue assays, the mediation of MSC-AS1/miR-3924/WNT5A/ß-catenin axis on KIRC cell proliferation, migration and migration was verified. This study revealed that MSC-AS1 regulates KIRC cell proliferation and migration via miR-3924/WNT5A/ß-catenin axis. MSC-AS1 might contribute to new strategies for KIRC treatment.
Asunto(s)
Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Carcinoma de Células Renales/metabolismo , Movimiento Celular/genética , Proliferación Celular/genética , Neoplasias Renales/metabolismo , MicroARNs/metabolismo , ARN Largo no Codificante/metabolismo , Vía de Señalización Wnt/genética , Proteína Wnt-5a/metabolismo , beta Catenina/metabolismo , Animales , Carcinoma de Células Renales/patología , Línea Celular Tumoral , Técnicas de Silenciamiento del Gen , Humanos , Neoplasias Renales/patología , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , ARN Largo no Codificante/genética , Transfección , Carga Tumoral/genética , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Lower serum level of 25-hydroxyvitamin D is common in older adults and associated with several negative outcomes. However, previous studies have indicated that 25-hydroxyvitamin D is associated with risk of type 2 diabetes, but presented controversial results.Studies in PubMed and EMBASE were searched update to June 2017 to identify and quantify the potential dose-response association between low 25-hydroxyvitamin D and risk of type 2 diabetes in older adults.Nine eligible studies involving a total of 34,511 participants with 2863 incident cases were included in this meta-analysis. Our results showed statistically significant association between lower 25-hydroxyvitamin D and type 2 diabetes in older adults [odds ratio (OR)â=â1.19, 95% confidence interval (95% CI): 1.08-1.32, Pâ=â.001]. In addition, we obtained the best fit at an inflection point of decrease 10âng/mL in piecewise regression analysis; the summary relative risk of type 2 diabetes in older adults for a decrease of 10âng/mL 25-hydroxyvitamin D was 1.06 (95% CI: 1.02-1.13, Pâ<â.001). Furthermore, subgroups analysis indicated that lower 25-hydroxyvitamin D was associated with a significant increment risk of type 2 diabetes in older adults in female (ORâ=â1.21, 95% CI: 1.04-1.40, Pâ=â.014) but not in male (ORâ=â1.11, 95% CI: 0.75-1.63, Pâ=â.615). Subgroup meta-analyses in study design, duration of follow-up, number of participants, and number of cases showed consistent with the primary findings.Lower 25-hydroxyvitamin D is associated with type 2 diabetes in older adults risk increment.
RESUMEN
Renal cell carcinoma (RCC) accounts for 3% of all cancer-related mortalities in adults. The risk factors for the development of RCC remain under investigation. Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis and is crucial for the development and metastasis of tumors, including RCC. VEGF gene polymorphisms may alter VEGF protein concentrations, affect the process of angiogenesis and may be involved in inter-individual variation in carcinogenesis. In the present study, a systematic review and meta-analysis were performed based on published case-control studies in order to estimate the association between VEGF gene polymorphisms and the susceptibility to RCC. A total of five studies that involved eight polymorphisms and were published between January 2000 and December 2012 were identified from PubMed. The results of this systematic review and meta-analysis indicate that the VEGF 936C/T, 1612G/A, -1154G/A, -2549I/D, -460T/C and 405G/C gene polymorphisms are not associated with the risk of RCC. There was no polymorphism in 702C/T and RCC and the -2578C/A gene polymorphism may be associated with an increased risk of RCC. However, due to the limitations of the present study, further high quality case-control studies are warranted to confirm these findings.